Skip to content

Electroencephalographic Neural Mechanisms of Accelerated cTBS in the Treatment of Treatment-Resistant Auditory Hallucinations in Schizophrenia

Electroencephalographic Neural Mechanisms of Accelerated cTBS in the Treatment of Treatment-Resistant Auditory Hallucinations in Schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110308
Enrollment
Unknown
Registered
2025-10-11
Start date
2025-10-11
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia with treatment-resistant auditory hallucinations

Interventions

Active a-cTBS group:The patient received real stimulation intervention. The patient received cTBS stimulation in the targeted brain region (the temporoparietal junction). The stimulus is issued in a c
Sham a-cTBS group:The patient received pseudo-stimulus intervention. During the treatment, the Magstim pseudo-stimulation coil is placed at the same position as the true stimulation coil. Its shape is

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for schizophrenia as stipulated in the Diagnostic and Statistical Manual of Mental Disorders (5th Edition); 2. Age: 18 to 50 years old; 3. The auditory hallucinations of the participants remain unresponsive to at least two typical antipsychotic drugs after at least 6 weeks of adequate treatment. 4. All patients had been continuously using antipsychotic drugs for at least 3 months during the study period, and the dosage remained unchanged throughout the study period. 5. Right-handed; 6. No comorbid mental or neurological disorders;

Exclusion criteria

Exclusion criteria: 1.Participants with severe physical illnesses, infectious diseases, or immune system disorders. 2.Participants with severe neurological disorders, intellectual disability, or organic brain diseases; 3.Pregnant or breastfeeding women; 4.Participants who have received electroconvulsive therapy within the past 3 months; 5.A history of epileptic seizures. 6.Participation in previous or ongoing research projects, such as transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulation interventions. 7.Implantation of metallic pacemakers, cardiovascular stents, intracranial electrodes, or similar devices. 8.Participants with claustrophobia or other fears related to magnetic resonance imaging (MRI) scanning.

Design outcomes

Primary

MeasureTime frame
Hoffman Auditory Hallucination Scale score;

Secondary

MeasureTime frame
Scores of the Adverse Event Record Form;Neurophysiological indices derived from electrophysiology;Scores on other clinical symptom and cognitive function-related scales;

Countries

China

Contacts

Public ContactFu Jiayi

Affiliated Kangning Hospital of Ningbo University

568073103@qq.com+86 574 2630 2565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026